Cargando…
The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia
Benign prostatic hyperplasia (BPH) is one of the most common genitourinary complications in men over 50 years of age and typically presents with lower urinary tract symptoms (LUTS). Classes of medications include α1-adrenoceptor blockers, 5α-reductase inhibitors, and phosphodiesterase 5 inhibitors....
Autores principales: | Gandhi, Jason, Weissbart, Steven J., Smith, Noel L., Kaplan, Steven A., Dagur, Gautam, Zumbo, Anna, Joshi, Gargi, Khan, Sardar Ali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5422692/ https://www.ncbi.nlm.nih.gov/pubmed/28540239 http://dx.doi.org/10.21037/tau.2017.03.57 |
Ejemplares similares
-
Transrectal ultrasound-guided extraction of impacted prostatic urethral calculi: a simple alternative to endoscopy
por: Amend, Gregory, et al.
Publicado: (2017) -
Testosterone and benign prostatic hyperplasia
por: Jarvis, Thomas R, et al.
Publicado: (2015) -
Etiologic classification, evaluation, and management of hematospermia
por: Suh, Yiji, et al.
Publicado: (2017) -
Commentary on “Solving the benign prostatic hyperplasia puzzle”
por: Thomas, Dominique, et al.
Publicado: (2018) -
Neoplastic diseases of the spermatic cord: an overview of pathological features, evaluation, and management
por: Dagur, Gautam, et al.
Publicado: (2017)